Skip to notes
CJC-1295 Visit Notes

The CJC-1295 half-life number depends on the form

If you searched “CJC 1295 no DAC half life,” here's the gap I'd put first: FDA's December 2024 review found no human studies of the forms without DAC. These sources don't give me a firm human half-life for that preparation.

The familiar number measured in days comes from the long-acting DAC form. It's useful, as long as it stays attached to the substance that researchers studied.

Side-window light falls across flour, a piece of dough and a folded red cloth on a white counter.
Flour, dough and a patch of window light.

What the measured number means

Teichman and colleagues' study in healthy adults estimated a half-life of 5.8–8.1 days for long-acting CJC-1295. Half-life is the time it takes for its level in blood to fall by half.

It doesn't mean the substance disappears when that time is up. It also doesn't tell us how long a useful effect lasts. A blood level isn't a measure of how someone feels.

That distinction matters if your real question is about sleep, recovery or an unwanted effect. The study's timing result can't answer all three. I'd write down which question I meant before carrying the figure into a conversation.

Why the no-DAC answer stays open

DAC means drug affinity complex. It's the added part that attaches to albumin, a protein in blood, and helps the peptide stay in circulation longer. The form without DAC lacks that part.

FDA calls these different active ingredients that can't be interchanged. Its review found no studies in people of the no-DAC forms. A timing estimate for another substance doesn't fill that gap, however often it gets repeated.

I wouldn't borrow a number from the body's natural hormone or a related peptide. The question is what was measured in people using this preparation. My notes on the names explain why I keep that wording intact.

“We don't have a measured answer here” can feel unsatisfying. It's still more useful than a precise-looking figure with the wrong evidence behind it.

Duration doesn't decide a schedule or safety

A longer half-life isn't automatically an advantage. FDA's review discusses possible blood-sugar, fluid-retention and immune risks, and long-term human safety remains unknown. A shorter duration doesn't settle those questions either.

I also keep half-life separate from a personal dosing schedule. The visit preparation page explains why study amounts and timing aren't instructions for a reader.

For an appointment, I'd bring two notes: the exact preparation and why its duration matters to me. That keeps the conversation tied to the concern, with room to discuss other explanations and options.